Background and Aim: After hepatitis B virus (HBV) e antigen (HBeAg) seroconversion, HBV-DNA continues to replicate, and HBeAg-negative patients still face the risk of liver disease progression.

These trials suggest that the rHEV vaccine is safe and can prevent clinically overt acute hepatitis E in high-risk populations. We herein review the different approaches in HEV-vaccine development ...

and antiviral activity of ABI-4334 in newly diagnosed or off-treatment chronic HBV patients irrespective of hepatitis B e antigens. “While this is an early read, these interim data reinforce the ...

Use the purifier to isolate the hepatitis B antigen produced by the yeast cells. The vaccine, once administered, will stimulate the immune system to attack the antigen (i.e., the protein coat).

Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the ...